The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE 10). In particular, the invention relates to combinations of 1-aryl-4- methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/05...

The present invention provides a method of treating a mammal with age-related macular degeneration (AMD) comprising administering a dosage of at least one of prostaglandin E1 (PGE1), papaverine, and an alpha-1-vasodilator, in a pharmaceutically acceptable carrier for a period of time effective to deliver a dosage effective to treat said AMD.

The present invention provides a method of treating a mammal with age-related macular degeneration (AMD) comprising administering a dosage of at least one of prostaglandin E1 (PGE1), papaverine, and an alpha-1-vasodilator, in a pharmaceutically acceptable carrier for a period of time effective to deliver a dosage effective to treat said AMD.

The present invention concerns a pharmaceutical composition comprising, by way of active substances: - papaverine, or one of the pharmaceutically acceptable salts thereof, and - at least one calcium antagonist from the class of dihydropyridines, or a pharmaceutically acceptable salt thereof

FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to combined antipyretic drug in form of rectal suppositories. Drug contains paracetamol, dimedrol and papaverine hydrochloride as active components, and lipophilic suppository base Suppocire (Suppocire NA-15) as auxiliary substance, with the following component ratio in g per 1 suppository with 2.0 g weight: paracetamol 0.3-0.5

The invention relates to pharmaceutics and medicine, more specifically to a wound-healing, burn-treating, regenerative and antiviral pharmaceutical composition for topical application, and can be used as a topically applied agent in dermatology, venereology, ophthalmology, etc. for treating lesions of the skin and mucous membranes caused by burns, herpesviruses, chlamydiae, mycoplasmas, etc., as well as in the comprehensive preventive treatment of the aforesaid diseases and for promoting the reg...

Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil apomorphine prostaglandin El pentolamine and papaverine.

A method for a same visit treatment for erectile dysfunction and premature ejaculation. The method includes: performing a diagnostic on the patient using physical conditions of the patient; determining a diagnostic group of the patient wherein each diagnostic group has corresponding conditions to the physical conditions of the patient; identifying an age group of the patient; selecting a first test dose of a pharmaceutical composition which corresponds to the age group and the diagnostic group o...